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ATP-gated P2X3 receptors are mostly expressed by nociceptive sensory neurons and
participate in transduction of pain signals. P2X3 receptors show a combination of fast
desensitization onset and slow recovery. Moreover, even low nanomolar agonist concen-
trations unable to evoke a response, can induce desensitization via a phenomenon called
“high afﬁnity desensitization.” We have also observed that recovery from desensitization
is agonist-speciﬁc and can range from seconds to minutes. The recovery process displays
unusually high temperature dependence. Likewise, recycling of P2X3 receptors in peri-
membrane regions shows unexpectedly large temperature sensitivity. By applying kinetic
modeling, we have previously shown that desensitization characteristics of P2X3 receptor
are best explained with a cyclic model of receptor operation involving three agonist
molecules binding a single receptor and that desensitization is primarily developing from the
open receptor state. Mutagenesis experiments suggested that desensitization depends on
a certain conformation of theATPbinding pocket and on the structure of the transmembrane
domains forming the ion pore. Further molecular determinants of desensitization have
been identiﬁed by mutating the intracellular N- and C-termini of P2X3 receptor. Unlike
other P2X receptors, the P2X3 subtype is facilitated by extracellular calcium that acts via
speciﬁc sites in the ectodomain neighboring the ATP binding pocket. Thus, substitution
of serine275 in this region (called “left ﬂipper”) converts the natural facilitation induced
by extracellular calcium to receptor inhibition. Given their strategic location in nociceptive
neurons and unique desensitization properties, P2X3 receptors represent an attractive
target for development of new analgesic drugs via promotion of desensitization aimed at
suppressing chronic pain.
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DESENSITIZATION OF INOTROPIC RECEPTORS
Desensitization is a loss of receptor responsiveness which devel-
ops with continuous presence of agonist. Desensitization is a
general phenomenon which can be observed in most mem-
brane receptor types, either metabotropic or ionotropic. Unlike
metabotropic receptors which desensitize mainly via recep-
tor internalization, thereby temporarily subtracting respon-
sive elements to the extracellular stimulus (Ferguson, 2001),
ionotropic receptor desensitization involves structural and func-
tional changes in membrane residing receptors. The funda-
mental properties of acetylcholine (ACh) ionotropic receptor
desensitization were originally described by Katz and Thesleff
(1957) working on the frog neuromuscular junction (for review
see Giniatullin et al., 2005) and can still be used to supply
important principles to understand desensitization of many
ionotropic receptors including those activated by extracellular
ATP.
Ionotropic ATP receptors comprise P2X1 – P2X7 subtypes
widely expressed in various tissues (Burnstock, 2013). The rate
of desensitization and recovery processes vary widely within the
family of P2X receptors (North, 2002). Thus, desensitization is
developing very fast up to complete, yet reversible, loss of response
in homotrimeric receptors composed of P2X1 and P2X3 subunits
(North, 2002; Coddou et al., 2011). In contrast, the other P2X
subtypes are less prone to desensitization. One goal of the present
review is to discuss how the strong desensitization process of P2X3
receptors can coexist with the function of P2X3 receptor activation
in pain signaling and whether facilitating desensitization might
actually be exploited for analgesic purposes. We aim at resolv-
ing this conundrum by taking into account the receptor kinetic
properties and dynamics.
P2X3 RECEPTORS UNIQUE PROPERTIES
P2X3 receptors are similar in some desensitization properties (fast
onset and slow recovery) to the P2X1 subtype. However, their
distinctive characteristics are listed below.
• Fast desensitization onset (ms range; similar time-course for
P2X1 subtype)
• Very slow (min range) recovery from desensitization (shared
with P2X1 subtype)
• High afﬁnity desensitization (HAD) by very low agonist con-
centrations without generating a macroscopic current
• Heteromerization of P2X3 with P2X2 subunits to generate
sustained non-desensitizing responses
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• Remarkable resistance of desensitization onset to changes in
temperature and divalent cation concentration
• Strong acceleration of recovery (resensitization) by increases in
extracellular Ca2+ levels and inhibition by extracellular Mg2+
• Speed of recovery highly dependent on temperature (higher
temperature, faster recovery)
• Recovery sensitive to signal transduction mechanisms and
controlled by the speciﬁc modulators
These properties are described in more detail in the following
sections of this review.
DESENSITIZATION ONSET OF P2X3 RECEPTORS
P2X3 receptors can be activated by different agonists such as ATP,
α,β-meATP, ATP-γ-S, β,γ-meATP, CTP, 2MeS-ATP and Bz-ATP
which can all operate as full agonists (Sokolova et al., 2004, 2006;
Pratt et al., 2005; Petrenko et al., 2011, for reviews see North, 2002;
Coddou et al., 2011; Fabbretti and Nistri, 2012). Despite their
different structures, all these compounds applied in high con-
centration can generate full size responses that, when recorded as
membrane currents in voltage clamp conditions, show very similar
fast decay (Sokolova et al., 2006).
The scheme of Figure 1 shows that the agonist-bound open
receptor can effect a dynamic transition to the closed, desen-
sitized state persisting even when the agonist has come off the
receptor. Thus, on P2X3 receptors, as expected from the clas-
sical model of desensitization by Katz and Thesleff (1957), the
desensitization onset is accelerated by increasing the agonist dose
(Sokolova et al., 2006) because the rate of this transition is strongly
dependent on the agonist concentration and it, therefore, ensures
that a large fraction of the available receptor population dwells
in this functionally inactive state. Nevertheless, unlike the phe-
nomenon observed with nicotinic receptors, the onset of P2X3
receptors desensitization is remarkably insensitive to temperature
changes (Khmyz et al., 2008). There are only a few experimental
manipulations which can speciﬁcally interfere with P2X3 receptor
desensitization onset. One drug is the anti-inﬂammatory anal-
gesic naproxen, which is widely used as an anti-migraine agent
and which can speed up the desensitization onset of recombinant
P2X3 receptors expressed in HEK cells (Hautaniemi et al., 2012,
see Figure 1). Conversely, acid pH slows down the development
of desensitization, although this effect might be indirectly due to
reduction of P2X3 receptor potency (Gerevich et al., 2007a).
SLOW RECOVERY FROM DESENSITIZATION
Restoration of the response after removal of agonist, indicating
P2X3 receptor recovery from ATP-induced desensitization, is very
slow and can take up to 20 min at room temperature (Cook et al.,
1998). This outstanding property makes P2X3 (and P2X1) recep-
tors very different from other ligand-gated receptors (Cook et al.,
1998). Even though the recovery occurs very slowly, it proceeds to
full return of P2X3 receptor response: this reversibility is a useful
criterion to distinguish desensitization from the irreversible run-
down which is a common feature of many ionotropic receptors
including the P2X1 subtype (Lewis and Evans, 2000).
We have previously shown that recovery of P2X3 receptors
from desensitization is an agonist-speciﬁc process (Sokolova
et al., 2004). It can be very fast for agonists like β,γ-meATP,
FIGURE 1 | A simplified kinetic scheme for P2X3 receptor operation
indicating resting, open and desensitized receptor states. Note
multiple factors accelerating (+, red arrow) or retarding (−, black arrow)
recovery from desensitization, while naproxen promotes desensitization
onset. Factors accelerating recovery are expected to facilitate ATP signaling
via P2X3 receptor activity, whereas factors retarding recovery (or
promoting desensitization onset) could provide the anti-nociceptive effect.
but unusually slow for 2MeS-ATP (Sokolova et al., 2006). Fur-
thermore, recovery displays distinctive properties from desen-
sitization onset because, in addition to its time-course, it
is modulated by factors such as temperature (Khmyz et al.,
2008), cibacron blue (Alexander et al., 1999), extracellular
Ca2+ (Cook et al., 1998) and others listed in Figure 1. The
independent modulation of desensitization onset and recov-
ery suggests that they are likely to have different determinants
(see details in the “Structural Determinants of Desensitiza-
tion”).
HIGH AFFINITY DESENSITIZATION
Apart from the “classical” desensitization arising from the open
receptor state, there is an additional process of slow onset desen-
sitization called “HAD” – that is, a low nanomolar concentration
of the agonist inhibits P2X3 receptor responses without evoking a
macroscopic current (McDonald et al., 2002; Sokolova et al., 2004,
2006; Pratt et al., 2005). We have shown that this phenomenon
is also agonist-speciﬁc, being particularly strong for the natural
agonist ATP (Sokolova et al., 2004, 2006). Thus, ATP is about a 10-
fold more potent inducer of HAD than α,β-meATP (IC50 2 and
20 nM, respectively), even though both agonists have almost the
same EC50 values (Sokolova et al., 2004).
Given that the ambient level of extracellular ATP in various
tissues is in the nanomolar range (Kuzmin et al., 1998; Lazarowski
et al., 2003), one might suggest that a fraction of P2X3 receptors
is continuously inactivated in vivo. Such inactivation could largely
reduce the ability of P2X3 receptor expressing neurons to detect
and generate nociceptive signal in response to acute ATP release.
Furthermore, diadenosine polyphosphates, that are endogenously
produced by bridging two adenosine moieties with a chain of
two or more phosphates, can act as powerful HAD inducers
(McDonald et al., 2002). This observation widens the range of
substances that can modulate desensitization of P2X3 receptors
and emphasizes the functional role of HAD as discussed in detail
in the present review.
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P2X3 ACTIVITY IS FACILITATED BY EXTRACELLULAR CALCIUM AND
INHIBITED BY MAGNESIUM
One outstanding feature of the P2X3 receptor is its unusual
sensitivity to extracellular Ca2+ which is speciﬁcally targeting
receptor desensitization. The exciting ﬁnding of the facilitatory
action of extracellular Ca2+ on P2X3 receptor was ﬁrst described
by McClesky’s group (Cook et al., 1998). Interestingly, Ca2+
selectively and positively controls the recovery stage of receptor
desensitization without changes in desensitization onset (Giniat-
ullin et al., 2003). The most intriguing ﬁnding is that there is a
sort of “memory” of the receptor system which remains in the
facilitated state for several mins after the initial transient contact
with the divalent cation (Cook et al., 1998). Such resensitization
by Ca2+ on P2X3 receptor is functionally opposite to the well
documented inhibitory action of Ca2+ on other P2X receptor
subtypes (Virginio et al., 1998; Ding and Sachs, 2000). In fact,
in the case of P2X2 receptors, extracellular Ca2+ rather promotes
desensitization (Ding and Sachs, 2000).
We have previously observed that, on native P2X3 recep-
tors, extracellular Mg2+ can produce an opposite effect to Ca2+
(Giniatullin et al., 2003). Thus, Mg2+ delays receptor recovery
from desensitization, while the onset of desensitization remains
unchanged. Ca2+-free solution has the similar inhibitory action
on receptor resensitization. As the modulatory effects were
observed with physiological concentrations of Ca2+, these ﬁnding
outline a potential role of this mechanism even in vivo.
Our recent study has demonstrated that a single aminoacid
(S275) within the left ﬂipper region of the P2X3 receptor
ectodomain is a likely determinant for the facilitatory action of
extracellular Ca2+ (Petrenko et al., 2011). Thus, in the A275
mutant, extracellular Ca2+ induces an inhibitory effect on P2X3
receptor mediated responses instead of the facilitation normally
seen with wildtype (WT) receptors.
UNUSUALLY HIGH TEMPERATURE SENSITIVITY
Another unexpected desensitization property of P2X3 receptors
was described in detail by Krishtal’s group. They showed that,
while the desensitization onset is almost temperature insensi-
tive, the recovery process is very temperature sensitive with a Q10
coefﬁcient of about 10 (Khmyz et al., 2008). The temperature sen-
sitivity of HAD is also high but clearly smaller than the one of the
recovery process (Khmyz et al., 2008). These ﬁndings suggest that,
unlike most in vitro experiments performed at room temperature,
the recovery process at normal body temperature is much faster
and that, in physiological conditions, the probability of repeated
receptor activation is strongly enhanced.
Interestingly, the recycling of P2X3 receptors in the peri-
membrane region measured by the TIRF/FRAP technique also
shows very high sensitivity to temperature (Pryazhnikov et al.,
2011).
KINETIC MODELING OF P2X3 RECEPTOR DESENSITIZATION
A formal description of P2X3 receptor behavior using kinetic
modeling allows the exploration of silent receptor conforma-
tions, prediction of new receptor desensitization properties, and
provides a mechanistic explanation for experimentally observed
phenomena. Modeling of P2X3 receptor kinetics clearly indicates
that a cyclic scheme of receptor reversible transitions modiﬁed
from the original proposal by Katz and Thesleff (1957) is the most
suitable to account for the experimental data which cannot be
adequately explained with linear or bifurcation models (Sokolova
et al., 2006). This model integrates all the main steps of P2X3
function such as binding, gating and desensitization, which are
presented in an over-simpliﬁed form in Figure 1.
In the complete receptor model with full activation caused by
three agonist molecules bound to it, the receptor transition into
the desensitized state occurs mainly from the open state. Fur-
thermore, this model can simulate HAD, implying the existence
of a single molecule bound desensitized state with high agonist
afﬁnity (Sokolova et al., 2006). As a result, the model fully repro-
duces all the main properties of the P2X3 receptor, including fast
desensitization, slow recovery and HAD.
The rate limiting role of agonist dissociation from the desen-
sitized state for resensitization obtained with this theoretical
approach accords with agonist unbinding from P2X3 receptors
measured using radiolabeled ATP (Pratt et al., 2005). Most impor-
tantly, the kinetic model predicts that desensitization, being the
next step after binding of ATP and channel opening, should
dependnot only on“intrinsic”desensitizing properties of theP2X3
receptor, but also on agonist binding and channel gating. This view
is essential when trying to ﬁnd out and analyze the numerous data
on structural determinants of desensitization.
To explain P2X3 receptor operation and in particular HAD,
Karoly et al. (2008) have subsequently proposed an allosteric
model that retains the cyclic scheme of Sokolova et al. (2006),
but it adds to it an additional transition, namely a recep-
tor open state occurring when two rather than three ATP
molecules are bound. Thus, Karoly et al. (2008) argue that their
revised model is the simplest way to explain increased afﬁn-
ity of non-occupied binding sites when receptors are partially
occupied. Future biophysical studies using microscopic record-
ing of single channel currents may be necessary to clarify this
proposal.
STRUCTURAL DETERMINANTS OF DESENSITIZATION
At membrane level functional homomeric P2X3 receptors are
assembled as trimers, whereby each subunit is composed of a
large extracellular loop containing the ATP binding domain, two
transmembrane domains and intracellular N- and C- termini (for
reviews see Khakh, 2001; Khakh and North, 2006; Kawate et al.,
2009, Fabbretti and Nistri, 2012). This complex structure has
been extensively probed to ﬁnd out the molecular determinants
of desensitization.
One pioneer study showed that, using recombinant receptors
expressed in Xenopus oocytes, chimeric P2X2 receptors contain-
ing P2X1 or P2X3 domains acquire strong desensitization, while
chimeric P2X1 or P2X3 receptors with P2X2 domains show very
weak desensitization (Werner et al., 1996). The domains nec-
essary to alter the desensitization phenotype include the most
hydrophobic segments of the molecules, which are thought to
be membrane-spanning segments (Werner et al., 1996). These
ﬁndings led Werner et al. (1996) to propose that desensitiza-
tion requires the interaction of these receptor long segments
(comprising 34 aminoacids).
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Many subsequent studies were focused on ﬁnding key residues
determining the desensitization process of P2X receptors. Thus,
it has been shown that certain C-terminus residues are important
to express the slow desensitization of P2X2 receptors (Koshimizu
et al., 1998; Smith et al., 1999). Likewise, the N-terminus half of
the P2X3 receptor ectodomain plays a role in the slow recovery
from desensitization (Zemkova et al., 2004).
Our previous study has identiﬁed several residues in the
ectodomain which determine the desensitization properties
including Glu111, Asp220, and Asp266 (Fabbretti et al., 2004).
By site-directed mutagenesis to alanine, it was possible to observe
a pleiotropy of receptor responses like fast onset combined with
either faster or slower recovery (Glu111Ala andAsp220Ala, respec-
tively), or very slow onset (resembling the non-desensitizing P2X2
receptor) combined with fast recovery (Asp266Ala). These various
combinations of kinetic properties provide additional evidence for
the existence of independent determinants of desensitization onset
and recovery.
Our in silico exploration of the P2X3 receptor molecular
model predicted that S275 within the ectodomain region termed
left ﬂipper as a contributor to ATP binding and suggested that
its manipulation would result in changes in the desensitization
properties (Petrenko et al., 2011). Indeed, substituting S275 with
alanine produces a mutant with slow desensitization onset, fast
resensitization and lack of HAD (Petrenko et al., 2011). In this
experiment, HAD remained minimal even with higher agonist
concentrations (to compensate for reduced potency), suggesting
that this residue is indeed important to express the inhibitory
action of low nanomolar concentrations of ATP. Substituting S275
with more hydrophobic aminoacids further slows down desen-
sitization onset and accelerates recovery, indicating these two
properties to be reciprocally interrelated (Petrenko et al., 2011).
Manipulations of the transmembrane P2X3 domains have
indicated additional contributors to shape desensitization. Thus,
substitution with alanine (or phenylalanine) of the highly con-
served Y37 yields initial fast desensitization with a large resid-
ual current, remarkably resistant to further desensitization
(Jindrichova et al., 2011; see Figure 2A). Unlike the WT, this long
lasting persistent current (highlighted by red arrow in Figure 2B)
is systematically observed in the Y37A mutant in the presence of
four different agonists (Figure 2B) applied at saturating concen-
trations that induce analogous amplitude of membrane current
(Figures 2C,D). The latter indicated that this unusual plateau-like
current is independent from the nature of the agonist. In sharp
contrast, at the end of the agonist application, a highly variable
(agonist-speciﬁc) rate of deactivation is observed (Figure 2B).
This variable deactivation is related to the EC50 values for each
agonist (Figure 2E). Furthermore, the rate of deactivation corre-
lates alsowith the rate of agonist dissociation from the desensitized
receptor state (fast deactivation, fast dissociation, see Sokolova
et al., 2006). Kinetic modeling may help to explain these unusual
phenomena by assuming facilitated re-opening of the P2X3 chan-
nels from the desensitized to the conducting states (Jindrichova
et al., 2011).
In conclusion, current evidence shows multiple determi-
nants of desensitization throughout the whole receptor structure
(ectodomain, transmembrane and intracellular termini).
Useful clues to the biophysical nature of desensitization may
also come by comparing P2X3 receptors with sister receptors con-
tainingotherP2X subunits. Thus, using voltage clampﬂuorometry
applied to the P2X1 subtype, which is also prone to fast desen-
sitization, Lörinczi et al. (2012) have proposed that the cys-rich
head domain of this receptor is involved in both channel acti-
vation and desensitization. In the P2X1 subtype, high sensitivity
to low doses of ATP is also reported, although desensitization in
this case develops after detectable membrane currents (Rettinger
and Schmalzing, 2003). Despite the fact that P2X7 receptors have
low afﬁnity for their natural ligand ATP (active at mM concentra-
tions), ongoing desensitization has also been proposed to exist in
this subtype, yet masked by the overlapping process of ion pore
widening (Khadra et al., 2013).
FUNCTIONAL ROLE OF DESENSITIZATION OF P2X3
RECEPTORS
Nowadays there is strong evidence that P2X3 receptors participate
in chronic pain, a most distressing clinical state often resistant
to treatment (Burnstock, 2001; North, 2004). In fact, P2X3
channels are almost exclusively expressed by nociceptive neurons
(Chen et al., 1995; Lewis et al., 1995), and impaired pain-evoked
responses (especially of inﬂammatory type) are observed in P2X3
knockout mice (Cockayne et al., 2000; Souslova et al., 2000). These
data accord with earlier reports that injection of α,β-meATP into
the rat paw evokes strong nociceptive behavior which is para-
doxically prevented by a previous application of the same agonist
(Bland-Ward and Humphrey, 1997), pointing to a functional role
of P2X3 receptor desensitization in shaping pain responses in vivo.
However, in view of the fast desensitization of P2X3 receptors and
the high likelihood of their HAD because of ambient ATP (and
its metabolites), one may wonder how to reconcile such charac-
teristics with a functional role of these receptors in sustained pain
signaling (North, 2004).
One possible explanation is that, in healthy subjects, the
main role of HAD in ATP-gated P2X3 receptors is to prevent
inappropriate excitation of nociceptive pathways (and associ-
ated pain sensitivity) when there is a high probability of ATP
release from surrounding tissues. In other words, HAD might be
viewed as an intrinsic mechanism of “anti-nociception” in normal
states, working in cooperation with fast desensitization to restrict
ATP-mediated signaling. This protective process might be impor-
tant in conditions like physical exercise when there is a continuous
release of ATP in muscles to the level comparable with EC50 of
P2X3 receptors (Hellsten et al., 1998; Mortensen et al., 2011).
Assuming a constitutive inhibition of P2X3 receptor activity by
ambient purines, only strong, burst-like ATP release can perhaps
represent a stimulus large enough to overcome any intrinsic anti-
nociceptive effect (Giniatullin et al., 2008). In contrast, in chronic
pain in man, particularly of inﬂammatory origin, P2X3 receptors
might play a direct pro-nociceptive role (Burnstock, 2001) because
the desensitization properties of P2X3 receptors could bemodiﬁed
by several cellular mechanisms that collectively or individually
promote nociceptive sensitization (Figure 1):
(i) removal of ambient ATP via extracellular NTDases;
(ii) decreased HAD;
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FIGURE 2 |The action of different agonists on the WT and Y37A
receptor. (A) Currents activated by 2 s application of β,γ-meATP,
α,β-meATP, ATP, or 2MeS-ATP (all 100 μM) on WT receptors. (B)
Currents activated by 2 min application of β,γ-meATP, α,β-meATP, ATP, or
2MeS-ATP (in keeping with higher potency, all at 10 μM) on Y37A
mutant receptors. Note similar peak amplitudes and plateau-like
components (red arrows) but different current decays during the washout
phase. (C,D) Histograms showing the mean amplitudes of peak currents
induced by different agonists on WT (C) or Y37A receptor (D). (E) Graph
showing a correlation between differential agonist-speciﬁc current decays
(measured after 30 s of washout) and corresponding EC50 values for
each agonist. Datapoints from 3 to 12 cells. Reproduced with
modiﬁcations from Jindrichova et al. (2011) with permissions from John
Wiley and Sons.
(iii) accelerated recovery from desensitization;
(iv) heteromerization with non-desensitizing P2X2 receptors.
Although the ﬁrstmechanism of sensitization has not been stud-
ied in relation to pain, its feasibility is indirectly supported by
experiments on taste buds (Vandenbeuch et al., 2013). In fact,
recent studies have shown expression of P2X3 receptors (along
with P2X2 ones) in nerves supplying the taste buds (Finger et al.,
2005). Using the NTDase-2 knockout mouse, it has been observed
that excessive levels of extracellular ATP generated in the taste
bud could inactivate nerve terminal P2X receptors and block the
taste response by promoting desensitization via a phenomenon
resembling HAD (Vandenbeuch et al., 2013). Thus, the extent of
breakdown and clearance of extracellular ATP may be important
to regulate nociceptive purinergic signaling.
As for the second mechanism of sensitization, evidence clearly
shows that resensitization of P2X3 receptors in vivo is much faster
than in vitro (Khmyz et al., 2008), and may be expected to occur
even faster if local inﬂammatory reaction raises tissue tempera-
ture. Furthermore, inﬂammatory cells like macrophages releasing
TNFα can further upregulate P2X3 receptor activity (Franceschini
et al., 2012, 2013). It is also noteworthy that humanP2X3 receptors
recover about twice faster than analogous rodent receptors (Pratt
et al., 2005). Finally, the P2X3 receptor recovery may be acceler-
ated, via release of neuropeptides and neurotrophins (Fabbretti
et al., 2006; D’Arco et al., 2007) and by extracellular acidiﬁcation
(Gerevich et al., 2007a) which occurs in inﬂammation and cancer
(Tannock and Rotin, 1989). Thus, the migraine mediator CGRP
not only largely increases the amplitude of P2X3 currents gen-
erated in nociceptive trigeminal neurons, but it also signiﬁcantly
speeds up recovery fromdesensitization via an intracellular kinase-
dependent process of P2X3 receptor phosphorylation (Fabbretti
et al., 2006; Giniatullin et al., 2008).
The possibility of the third mechanism of sensitization via
reduced HAD is supported by decreased inhibitory action of
nanomolar ATP at higher temperature (Khmyz et al., 2008).
Finally, enhanced expression of heteromeric P2X2/3 recep-
tors producing typically non-desensitizing plateau currents might
be the fourth mechanism of sensitization contributing to noci-
ceptive signaling (North, 2004). However, recent study revealed
the prevailing expression of P2X3 subunits in dorsal root
ganglion neurons in primates, including human sensory neurons
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(Serrano et al., 2012). Thus, the contribution of P2X2/3 recep-
tors to chronic pain is probably more important at the level of
nociceptive pathways within the spinal dorsal horn as indicated by
the inhibition of nociceptive neuron ﬁring by A-317491, a potent
P2X2/3 antagonist (Xu et al., 2012).
A proposal for the physiological role of desensitization should
also include mechanisms which augment this inhibitory process.
Indeed, recovery from desensitization can be delayed via GPCR
signaling (Figure 1) involving P2Y receptors (Gerevich et al.,
2007b), GABAB receptors (Sokolova et al., 2003) and unidentiﬁed
membrane receptors activated by extracellular cAMP (Mamenko
et al., 2010). These mechanisms may be additional to the intrinsic
inhibition of P2X3 receptor activity via C-terminal Src inhibitory
kinase (Csk)-mediated tyrosine phosphorylation of the receptor
(D’Arco et al., 2009). Future studies should address whether in
chronic painmodels there is a disruption in the intricatemolecular
mechanisms regulating P2X3 expression and function.
ANALGESIC DRUGS PROMOTING DESENSITIZATION OF P2X3
RECEPTORS
INFLAMMATORY AND NEUROPATHIC PAIN
The anti-nociceptive action of the selective P2X3 antagonist A-
317491 in inﬂammatory and neuropathic pain was ﬁrst reported
in a study aimed at counteracting chronic pain in animal models
(Jarvis et al., 2002). The traditional pharmacological approach to
anti-nociception is usually based on the development of receptor
antagonistswith goodbioavailability, high speciﬁcity, andminimal
side-effects. One such example is a novel selective P2X3/P2X2/3
receptor antagonist AF-353 which is orally bioavailable (Gever
et al., 2010). Other potential analgesic agents with different struc-
ture based on P2X3 receptor antagonism are reviewed by Gum
et al. (2012) and by A. P. Ford in this series. Some of these com-
pounds are already investigated in clinical trials, although none
of them has yet received statutory approval by regulatory agencies
for human use (Ford, 2012). A new line in drug development
for the prevention of P2X3 mediated pain should target facil-
itation of desensitization. In fact, Bland-Ward and Humphrey
(1997) have previously shown that an analgesic effect could be
induced by injection of the full P2X3 agonist, α,β-meATP after
an initial pro-nociceptive effect. More promising clues for pain
suppression treatment may, however, come from the use of pro-
moters of desensitization which show little or no agonist activity.
Thus, purotoxin-1, a peptide recently isolated from the Asian wolf
spider Geolycosa, powerfully inhibits P2X3 receptors by strongly
promoting their desensitized state and provides effective anti-
nociception in various pain models in vivo (Grishin et al., 2010)
while the antagonist P1, P5-di[inosine-5′] pentaphosphate binds
to the desensitized state of the P2X3 receptor in DRG neurons
(Ford et al., 2005).
MIGRAINE AND TRIGEMINAL PAIN
Mg2+ can hardly be considered as a selective anti-migraine agent,
and is typically known to be the endogenous blocker of NMDA
channels (Nowak et al., 1984). There are, however, repeated sug-
gestions to include this agent in the complex therapy of trigeminal
migraine pain (this subject has been extensively discussed by
Pardutz and Vecsei, 2012; and Mauskop and Varughese, 2012). As
Mg2+ inhibits desensitizing ATP-evoked currents in rat cultured
sensory neurons (Giniatullin et al., 2003), this effect might be
considered to contribute to its analgesic action in vivo (Crosby
et al., 2000). Given that Mg2+ speciﬁcally interferes with desen-
sitized receptor states, one could expect the use-dependent
anti-nociceptive action of this divalent cation in pain mediated
by high concentrations of ATP acting on the P2X3 receptor. Of
course, modulation by Mg2+ of P2X3 receptor activity may be
complementary to the divalent cation role in NMDA receptor
function that is thought to be dysregulated in trigeminal ganglia
and underlying pain sensitization (Laursen et al., 2013).
The high expression of P2X3 receptors by the vast majority of
trigeminal sensory neurons (Simonetti et al., 2006) provides the
molecular substrate for P2X3 mediated trigeminal pain includ-
ing migraine (Giniatullin et al., 2008). In experimental model of
trigeminal pain in vitro, expression of P2X3 membrane recep-
tors by trigeminal neurons is ampliﬁed by the migraine mediator
CGRP that operates via intracellular kinases and enhanced P2X3
receptor trafﬁcking from intracellular compartments (Fabbretti
et al., 2006). Likewise, in transgenic mice expressing human
mutated P/Q calcium channels as observed in Familial Hemiplegic
Migraine type 1, the activity of P2X3 channels is constitutively
enhanced (Nair et al., 2010) probably because of the higher back-
ground release of CGRP as shown by the phenotype reversal
evoked by a CGRP receptor antagonist (Hullugundi et al., 2013).
To further support the role of PX3 receptors inmigraine pain, there
are data obtainedwithwell-established anti-migraine drugs. Thus,
naproxen, a popular anti-headache analgesic, directly inhibits
P2X3 receptors by facilitating receptor desensitization (Figure 1),
an inhibitory effect that is potentiated in the presence of the
algogen nerve growth factor (Hautaniemi et al., 2012), the level
of which is elevated in patients with chronic migraine (Jang et al.,
2011).
CANCER PAIN
Accumulating evidence suggests the involvement of P2X3 recep-
tors in bone tissue cancer pain. The bone has a very speciﬁc
environment including diverse cell populations and a special-
ized hormonal control by parathyroid hormone and parathyroid
hormone-related protein which regulate Ca2+ release from osteo-
clasts (Soki et al., 2012). Thus, in bone cancer there is a massive
release of Ca2+ leading eventually to hypercalcaemia which as
mentioned above is a potent and unique mechanism to facil-
itate, via resensitization, the function of P2X3 receptors. In
some pathological conditions, for instance, during parathy-
roid hormone-related protein-mediated hypercalcemic crisis, the
serumCa2+ can raise fromnormal level of ∼1.5mMup to 4.8mM
(Rahil and Khan, 2012). There can be also malignancy-associated
hypercalcemia, often associated with headache when the level of
Ca2+ released from osteoclasts is rising locally within the bone
(Basso et al., 2011). When the intense ATP release coincides with
local enhancement of extracellular Ca2+ this could result in a
strong nociceptive ﬁring through increased activity of P2X3 recep-
tors. The antagonism of Ca2+ effect on P2X3 receptor by Mg2+
(Giniatullin et al., 2003) can provide a rationale for the high anal-
gesic efﬁciency of the latter in cancer pain (Crosby et al., 2000).
Thus, the selective P2X3, P2X2/3 receptor antagonist A-317491
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transiently attenuates cancer-induced bone pain in mice, but has
no effect at the late stage of bone cancer (Hansen et al., 2012). Bone
cancer pain in rats is reduced by the blockade of P2X3 and P2X2/3
receptors withAF-353 (Kaan et al., 2010). Furthermore, there is an
increased expression of P2X3 receptors in CGRP immunoreactive
nerves during tumor growth suggesting their role in cancer-related
pain (Gilchrist et al., 2005). Likewise, P2X3 receptors are function-
ally up-regulated in dorsal root ganglion neurons of a rat model
of bone cancer (Wu et al., 2012).
CONCLUSION
Desensitization of nicotinic ACh receptors is now considered an
important process for neuronal signaling in health and disease
(Giniatullin et al., 2005). In fact, there are ongoing efforts to
develop drugs (“silent desensitizers”; Buccafusco et al., 2009) to
modulate cholinergic function via receptor desensitization. The
path is, therefore, open to look for chemical agents to desensi-
tize P2X3 receptors selectively and to discover their impact on
physiological or pathological conditions.
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